Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GENOCEA BIOSCIENCES, INC.

(GNCA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
2.34(c) 2.3(c) 2.2(c) 2.25(c) 2.29(c) Last
245 504 95 282 121 481 118 587 50 422 Volume
-0.85% -1.71% -4.35% +2.27% +1.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -49,8 M - -
Net cash position 2021 93,0 M - -
P/E ratio 2021 -3,08x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -56,9 M - -
Net cash position 2022 44,0 M - -
P/E ratio 2022 -2,97x
Yield 2022 -
Capitalization 125 M 125 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 72
Free-Float 91,1%
More Financials
Company
Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The CompanyÔÇÖs Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each personÔÇÖs tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an... 
More about the company
Ratings of Genocea Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about GENOCEA BIOSCIENCES, INC.
06/22GENOCEA BIOSCIENCESá : Annual Shareholder Meeting
PU
06/07GENOCEA BIOSCIENCESá : Presents Promising Long-term Results from GEN-009 Neoanti..
AQ
06/04GENOCEA BIOSCIENCESá : Presents Promising Long-term Results from GEN-009 Neoanti..
PU
06/04GENOCEA BIOSCIENCESá : GEN-009 Neoantigen Vaccine Phase 1 Trial Shows Long-Term ..
MT
06/04GENOCEA BIOSCIENCES, INC.á : Regulation FD Disclosure (form 8-K)
AQ
06/04Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine ..
GL
04/30GENOCEA BIOSCIENCESá : Files $300 Million Mixed Shelf
MT
04/29GENOCEA BIOSCIENCES : Q1 Earnings Snapshot
AQ
04/29GEN-011 AND GEN-009 IMMUNO-ONCOLOGY : 30 a.m. E.T
PU
04/29GENOCEA BIOSCIENCES, INC.á : Results of Operations and Financial Condition (form..
AQ
04/29GENOCEA BIOSCIENCESá : Provides First Quarter 2021 Corporate Update
AQ
04/27GENOCEA BIOSCIENCESá : First Quarter 2021 Financial Results
PU
04/22Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast
GL
04/14GENOCEA BIOSCIENCES, INC.á : Change in Directors or Principal Officers (form 8-K..
AQ
04/10Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Mee..
GL
More news
News in other languages on GENOCEA BIOSCIENCES, INC.

- No features available -

More news
Analyst Recommendations on GENOCEA BIOSCIENCES, INC.
More recommendations
Chart GENOCEA BIOSCIENCES, INC.
Duration : Period :
Genocea Biosciences, Inc. Technical Analysis Chart | GNCA | US3724274010 | MarketScreener
Technical analysis trends GENOCEA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,29 $
Average target price 6,68 $
Spread / Average Target 192%
EPS Revisions
Managers and Directors
NameTitle
William D. Clark President, Chief Executive Officer & Director
Diantha Duvall Chief Financial Officer
Kenneth M. Bate Chairman
Jessica Baker Flechtner Chief Scientific Officer
Thomas Andrew Davis Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENOCEA BIOSCIENCES, INC.-5.37%122
MODERNA, INC.111.89%88 882
LONZA GROUP AG14.06%52 367
IQVIA HOLDINGS INC.36.17%46 761
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-9.40%28 797